Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Top 5 High-Yield S&P 500 Stocks to Buy for 2023
by Rajani Lohia
With risks of elevated inflation, rising interest rates and geopolitical turmoil, investments in high-yield dividend stocks offer a defensive play. Stocks like GILD, CAG, CAT, CFG and NRG look attractive.
Gilead Sciences (GILD) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
by Zacks Equity Research
bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
by Zacks Equity Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
4 Stocks With Impressive Interest Coverage Ratio to Snap Up
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Sprouts Farmers (SFM), Fortinet (FTNT), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are strong enough to meet financial obligations.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
by Zacks Equity Research
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Esperion (ESPR) Reports Positive Data From CLEAR Study
by Zacks Equity Research
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands
by Zacks Equity Research
Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog.
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
by Zacks Equity Research
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
5 Dividend Stocks to Allay Fears of a More-Aggressive Fed
by Tirthankar Chakraborty
As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prudent.
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
by Zacks Equity Research
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
by Zacks Equity Research
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
by Zacks Equity Research
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.